Literature DB >> 2016478

Restenosis after coronary angioplasty: an overview.

R M Califf1, D F Fortin, D J Frid, W R Harlan, E M Ohman, J R Bengtson, C L Nelson, J E Tcheng, D B Mark, R S Stack.   

Abstract

Despite substantial basic and clinical efforts to address the problem of restenosis after percutaneous coronary intervention, effective preventive therapies have not yet been developed. Nevertheless, the accumulated information has provided much insight into the process of restenosis in addition to allowing standards to be developed for adequate clinical trials. The pathophysiology of restenosis increasingly appears to be distinct from that of primary atherosclerosis. Restenosis involves elastic recoil, incorporation of thrombus into the lesion and fibrocellular proliferation in varying degrees in different patients. Lack of an animal model that satisfactorily mimics restenosis is a major impediment to further understanding of the process. Clinical studies are hampered by difficulties in finding a single unifying definition of restenosis and by variable methods of reporting follow-up. Reporting of clinical outcomes of all patients in angiographic substudies would allow a more satisfactory interpretation of the results of clinical trials. Current noninvasive test results are not accurate enough to substitute for angiographic and clinical outcome data in intervention trials. In the majority of observational studies, only diabetes and unstable angina have emerged as consistently associated with restenosis; whereas most of the standard risk factors for atherosclerosis have a less consistent relation. Disappointingly, the new atherectomy and laser technologies have not affected restenosis rates. The one possible exception is coronary stenting, as a result of the larger luminal diameter achieved by the placement of the stent. In conclusion, although substantial continued effort is necessary to explore the basic aspects of cellular proliferation and mechanical alteration of atherosclerotic vessels, attention to the principles of clinical trials and observation are required to detect the impact of risk factors and interventions on the multifactorial problem of restenosis. Adequate sample sizes, collection of clinical and angiographic outcomes and factorial study designs hold promise for unraveling this important limitation of percutaneous intervention.

Entities:  

Mesh:

Year:  1991        PMID: 2016478     DOI: 10.1016/0735-1097(91)90933-z

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  20 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Antithrombotic Therapy during Percutaneous Coronary Intervention.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Monte Carlo dose simulation for intracoronary radiation therapy with a rhenium 188 solution-filled balloon with contrast medium.

Authors:  Eun-Hee Kim; Dae Hyuk Moon; Seung-Jun Oh; Chang-Woon Choi; Sang-Moo Lim; Myeong-Ki Hong; Seong-Wook Park
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

4.  Antiproliferative effects of a c-myc antisense oligonucleotide on human arterial smooth muscle cells.

Authors:  M Ebbecke; C Unterberg; A Buchwald; S Stöhr; V Wiegand
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

5.  Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice.

Authors:  B Zhu; D G Kuhel; D P Witte; D Y Hui
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Endovascular irradiation prevents smooth muscle cell proliferation and neointimal hyperplasia in rabbits.

Authors:  L Xu; Y Wu; G Feng; M Oguchi; H Yokota; T Nakagawa; I Yamamoto
Journal:  J Tongji Med Univ       Date:  1999

7.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Myocardial Perfusion SPECT Imaging in Patients after Percutaneous Coronary Intervention.

Authors:  Panagiotis Georgoulias; Varvara Valotassiou; Ioannis Tsougos; Nikolaos Demakopoulos
Journal:  Curr Cardiol Rev       Date:  2010-05

9.  Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention [corrected] in patients with coronary artery disease.

Authors:  Norihito Inami; Shosaku Nomura; Takayuki Shimazu; Kenichi Manabe; Yutaka Kimura; Toshiji Iwasaka
Journal:  J Thromb Thrombolysis       Date:  2007-05-08       Impact factor: 2.300

10.  Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease.

Authors:  Daisuke Satoh; Norihito Inami; Takayuki Shimazu; Takayuki Kajiura; Kohichi Yamada; Toshiji Iwasaka; Shosaku Nomura
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.